Gewichtsmanagement 2 min read

GLP-1 Peptide Side Effects: What the Research Shows

META-TITLE: [TODO: GLP-1 Peptide Side Effects — What the Research Shows | Brand]
META-DESC: [TODO: Evidence-based overview of GLP-1 peptide side effects, incidence rates, mechanisms, and research considerations.]

[TODO] Hook — side effects are the most searched topic around GLP-1 peptides, understanding mechanisms helps optimize research protocols

[IMAGE: Body diagram showing where GLP-1 side effects manifest — brain, thyroid, stomach, pancreas, gallbladder]

Gastrointestinal Effects

[TODO] Nausea — most common (20-44%), mechanism: delayed gastric emptying + central signaling
[TODO] Vomiting — 10-24%, dose-dependent, usually first 4-8 weeks
[TODO] Diarrhea / constipation — varies by compound, altered GI motility
[TODO] Mitigation — slow titration, small meals, hydration, timing

Pancreatic Considerations

[TODO] Acute pancreatitis — 0.1-0.3% incidence, monitor lipase/amylase
[TODO] Pancreatic cancer concern — epidemiological data inconclusive, long-term monitoring
[TODO] Contraindications — personal/family history of pancreatitis

Thyroid & Endocrine

[TODO] C-cell tumors — rodent data (not replicated in primates), MTC boxed warning
[TODO] Calcitonin monitoring — not routinely recommended but discussed
[TODO] MEN2 / MTC family history — absolute contraindication

Hepatobiliary Effects

[TODO] Gallstones — increased incidence with rapid weight loss, not GLP-1 specific
[TODO] Cholecystitis — monitor for RUQ pain, especially at higher doses
[TODO] Liver enzymes — generally improve (NAFLD benefit) but monitor

[IMAGE: Timeline graphic showing typical side effect progression — week 1-4 onset, week 8-12 adaptation]